Unicycive Therapeutics Files 8-K
Ticker: UNCY · Form: 8-K · Filed: Jun 30, 2025 · CIK: 1766140
| Field | Detail |
|---|---|
| Company | Unicycive Therapeutics, Inc. (UNCY) |
| Form Type | 8-K |
| Filed Date | Jun 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-condition, corporate-events
TL;DR
Unicycive Therapeutics filed an 8-K on 6/30/25 covering financials and other events.
AI Summary
On June 30, 2025, Unicycive Therapeutics, Inc. filed an 8-K report detailing significant corporate events. The filing includes information on the company's results of operations and financial condition, as well as other events and financial statements and exhibits. The report was filed as of June 30, 2025.
Why It Matters
This 8-K filing provides an update on Unicycive Therapeutics' financial condition and operational events, which is crucial for investors to assess the company's current status and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K report which typically contains factual corporate information and does not inherently signal significant risk.
Key Players & Entities
- Unicycive Therapeutics, Inc. (company) — Registrant
- June 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40582 (document_id) — Commission File Number
- 813638692 (tax_id) — IRS Employer Identification No.
- 4300 El Camino Real, Suite 210 (address) — Principal executive offices
- Los Altos, CA 94022 (address) — Principal executive offices
- (650) 351-4495 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Unicycive Therapeutics, Inc.'s results of operations and financial condition, as well as other events and financial statements and exhibits, as of June 30, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on June 30, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Unicycive Therapeutics, Inc.
In which state was Unicycive Therapeutics, Inc. incorporated?
Unicycive Therapeutics, Inc. was incorporated in Delaware.
What is the company's principal executive office address?
The company's principal executive office is located at 4300 El Camino Real, Suite 210, Los Altos, CA 94022.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 30, 2025 regarding Unicycive Therapeutics, Inc. (UNCY).